Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
8.80
+0.52 (6.28%)
At close: May 12, 2025, 4:00 PM
8.87
+0.07 (0.80%)
After-hours: May 12, 2025, 7:59 PM EDT

Arcus Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Net Income
-391-283-307-26753-123
Upgrade
Depreciation & Amortization
10108643
Upgrade
Asset Writedown & Restructuring Costs
-20----
Upgrade
Loss (Gain) From Sale of Investments
-23-25-19-5-
Upgrade
Stock-Based Compensation
727673655522
Upgrade
Other Operating Activities
1010101131
Upgrade
Change in Accounts Receivable
202815704-17-1
Upgrade
Change in Accounts Payable
73-18-59
Upgrade
Change in Unearned Revenue
-42-56-68-112-368188
Upgrade
Change in Other Net Operating Assets
3747-17231412
Upgrade
Operating Cash Flow
-300-170-306438-256111
Upgrade
Capital Expenditures
-3-6-24-6-26-3
Upgrade
Investment in Securities
120-78218-40422-431
Upgrade
Other Investing Activities
----3--
Upgrade
Investing Cash Flow
117-84194-413-4-434
Upgrade
Long-Term Debt Issued
-47----
Upgrade
Net Debt Issued (Repaid)
4747----
Upgrade
Issuance of Common Stock
1502373323232439
Upgrade
Repurchase of Common Stock
-7-7----
Upgrade
Other Financing Activities
---105-
Upgrade
Financing Cash Flow
1902773333237439
Upgrade
Net Cash Flow
723-7958-23116
Upgrade
Free Cash Flow
-303-176-330432-282108
Upgrade
Free Cash Flow Margin
-214.89%-68.22%-282.05%385.71%-73.63%138.46%
Upgrade
Free Cash Flow Per Share
-3.25-1.95-4.466.00-3.811.97
Upgrade
Cash Interest Paid
11----
Upgrade
Cash Income Tax Paid
--53--
Upgrade
Levered Free Cash Flow
-174-41.25-187.75617.75-644.7540.73
Upgrade
Unlevered Free Cash Flow
-171.5-38.75-186.5619-644.7540.73
Upgrade
Change in Net Working Capital
-22-7531-729711.5-96.23
Upgrade
Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q